Illumina Newsroom

Illumina Granted Access to Synaffix's Metal-Free Click Chemistry Technology

MT NewswiresDec 4 06:12 ET

Illumina To Webcast Upcoming Investor Conference

IlluminaDec 4 00:00 ET

Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)

Earnings Call TranscriptsDec 3 16:41 ET

Illumina Inc. Stock Outperforms Competitors On Strong Trading Day

MarketWatchDec 2 17:27 ET

Trump's Unusual Pick for NIH Director May Be a Win for These Stocks -- Barrons.com

Barron'sNov 27 14:26 ET

Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?

Simply Wall StNov 26 09:59 ET

Illumina, Inc. (ILMN): Constrained Spending in Pharmaceutical Industry Pressures Shares Despite Strong Niche Position

Yahoo FinanceNov 25 17:41 ET

MYGN Stock Up on Integration of HRD Platform Into Illumina's TSO 500 V2

Zacks Nov 25 06:05 ET

Myriad Genetics Announces The Incorporation Of Its HRD Platform In Illumina's Updated Gene Panel Assay

BenzingaNov 20 16:33 ET

Myriad Genetics Announces Incorporation of Its Proprietary HRD Platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight Oncology 500 V2

Globe NewswireNov 20 16:30 ET

If RFK Jr. Cuts Science Funding, These Instrument Makers May Suffer -- Barrons.com

Barron'sNov 20 15:29 ET

Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Wolfe Research 2024 Healthcare Conference (Transcript)

Earnings Call TranscriptsNov 20 14:09 ET

Because Mena announced the expansion of the TruSight Oncology product line.

The latest solutions will be showcased at the annual meeting of the Molecular Pathology Association for comprehensive variant analysis of tumors. Research and share led by customers of Illumina will provide the latest tumor analysis evidence and related content. San Diego, California, USA, November 20, 2024 /PR Newswire/ -- Illumina, a global leader in DNA sequencing and array technologies (nasdaq: ILMN), today announced the launch of the new version of its flagship cancer research testing product, TruSight Oncology 500 v2 (TSO 500 v2), for practical applications.

PR NewswireNov 19 21:00 ET

Express News | Illumina Inc: Trusight Oncology 500 V2 Assay Is Currently Under Development, Global Release Planned for Mid-2025

ReutersNov 19 09:16 ET

Express News | Illumina Announces Expansion of Trusight Oncology Portfolio

ReutersNov 19 09:15 ET

Illumina Announces Expansion of TruSight Oncology Portfolio

IlluminaNov 19 00:00 ET

Is Illumina, Inc. (ILMN) the Best Immunotherapy Stock to Buy Now?

Yahoo FinanceNov 18 09:16 ET

Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness

Seeking AlphaNov 15 15:55 ET

Citi Maintains Illumina(ILMN.US) With Buy Rating, Maintains Target Price $190

Moomoo NewsNov 14 06:31 ET · Ratings

Illumina Coverage Resumed at Equal Weight by Morgan Stanley

Seeking AlphaNov 12 15:13 ET